|
BBS12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.94330000002907E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.74290000001898E-06 |
| Normal-vs-Stage2 |
4.782100E-04 |
| Normal-vs-Stage3 |
2.02309999999262E-05 |
| Normal-vs-Stage4 |
7.54040000439105E-08 |
| Stage1-vs-Stage2 |
4.059200E-01 |
| Stage1-vs-Stage3 |
9.506000E-01 |
| Stage1-vs-Stage4 |
2.809800E-02 |
| Stage2-vs-Stage3 |
5.448200E-01 |
| Stage2-vs-Stage4 |
4.095600E-02 |
| Stage3-vs-Stage4 |
7.445500E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.00920000001281E-06 |
| Normal-vs-AfricanAmerican |
3.469700E-02 |
| Normal-vs-Asian |
1.14259999994815E-06 |
| Caucasian-vs-AfricanAmerican |
1.623250E-01 |
| Caucasian-vs-Asian |
5.753200E-01 |
| AfricanAmerican-vs-Asian |
1.191400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.46109999999522E-05 |
| Normal-vs-Female |
1.35639999998549E-06 |
| Male-vs-Female |
3.784600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.04170000003734E-06 |
| Normal-vs-Age(41-60Yrs) |
4.29560000000384E-05 |
| Normal-vs-Age(61-80Yrs) |
1.20650000001721E-06 |
| Normal-vs-Age(81-100Yrs) |
2.224100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.902500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.569200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.602600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.084380E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.547400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.720400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.545900E-02 |
| Classical-VS-Follicular |
2.177200E-01 |
| Classical-VS-Other |
9.958200E-01 |
| Classical-VS-Normal |
4.12059999999048E-06 |
| Tall-VS-Follicular |
9.839100E-03 |
| Tall-VS-Other |
3.449000E-01 |
| Tall-VS-Normal |
1.81400000021092E-07 |
| Follicular-VS-Other |
6.944600E-01 |
| Follicular-VS-Normal |
3.958000E-04 |
| Other-VS-Normal |
6.329700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.96954999999166E-05 |
| Normal-vs-N1 |
2.49139999963788E-07 |
| N0-vs-N1 |
2.780200E-02 |
|
|
